GeneDx Advances Genomic Newborn Screening with Strong GUARDIAN Study Results
Event summary
- GeneDx presented new findings at ICoNS 2026 demonstrating progress in genomic newborn screening (gNBS) scalability and accessibility.
- GUARDIAN study enrolled 30,000 newborns, with 72.3% parent participation and 76% representing non-European genetic ancestry.
- gNBS identified conditions missed by standard screening, including Long QT syndrome, leading to preventive treatments for infants and family members.
- BRIDGES-NBS program, funded by NIH, will begin enrolling this month across eight states and territories.
The big picture
GeneDx's advancements in genomic newborn screening position it at the forefront of a shift towards proactive, preventive healthcare. The company's collaboration with leading academic and public health institutions underscores the growing recognition of genomics in early disease intervention. As gNBS moves from research to clinical practice, GeneDx's role in building the evidence base could drive broader industry adoption and regulatory support.
What we're watching
- Scalability Challenges
- How GeneDx will address the operational and logistical hurdles of scaling gNBS across diverse populations and healthcare systems.
- Regulatory Approval
- Whether the positive outcomes from GUARDIAN and BRIDGES-NBS will accelerate regulatory approvals for broader clinical implementation of gNBS.
- Market Adoption
- The pace at which healthcare providers and insurers adopt gNBS, given the evidence of its clinical impact and cost-effectiveness.
Related topics